SCG2 has been increasingly demonstrated to be highly expressed in colorectal carcinoma, renal carcinoma, melanoma, as well as other cancers (Fukumoto et al., 2023; Steinfass et al., 2023; Weng et al., 2022). Here, SCG2 is linked to melanoma.